TrialThe Lancet. Oncology2022

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.

Georgina V Long et al.PubMed ↗Publisher ↗

No numbers read from the abstract.